文献类型：期刊文献

英文题名：Efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of gastric cancer: a meta-analysis of randomized controlled trials

作者：Wang, Gongchen[1];Yang, Binfeng[1];Fu, Zhaoyuan[1];Wang, Xin[1];Zhang, Zhiming[1]

第一作者：王功臣

通信作者：Zhang, ZM[1]

机构：[1]Gansu Univ Chinese Med, Affiliated Hosp, 732 West Jiayuguan Rd, Lanzhou 730000, Gansu, Peoples R China

第一机构：甘肃中医药大学第二附属医院

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Affiliated Hosp, 732 West Jiayuguan Rd, Lanzhou 730000, Gansu, Peoples R China.|[10735b845793de6ae2b30]甘肃中医药大学第二附属医院;[10735]甘肃中医药大学;

年份：2019

卷号：24

期号：6

起止页码：614

外文期刊名：INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY

收录：;Scopus(收录号：2-s2.0-85064225255);WOS:【SCI-EXPANDED(收录号:WOS:000468336100003)】；

语种：英文

外文关键词：Gastric cancer; Oxaliplatin; Cisplatin; Chemotherapy

摘要：BackgroundCisplatin played an important role in the treatment of gastric cancer (GC). Oxaliplatin has been shown to be at least as effective as cisplatin for GC, with less toxicity and a better tolerability profile. We performed a meta-analysis to compare the efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of GC.MethodsDatabases of CNKI, CBM, VIP, Wanfang, PubMed, Embase, Cochrane Library were searched for eligible literatures from their establishments to November 2018. Randomized controlled trials that compared the efficacy and safety of oxaliplatin-based regimen with that of cisplatin-based regimen in the treatment of GC were included. Statistical analyses were calculated using RevMan 5.3 software.ResultsSeven randomized controlled trials including 2297 patients were included. Compared with cisplatin-based regimen intervention in GC, oxaliplatin-based regimen treatment was able to significantly improve the partial response rate (OR=1.26, 95% CI 1.07-1.49; p=0.007), disease progression rate (OR=0.41, 95% CI 0.25-0.66; p=0.0002) and 1-year survival (OR=1.25, 95% CI 1.00-1.56; p=0.05). The toxicities of hematopoietic system were significantly higher in cisplatin-based regimen group (OR=0.6, 95% CI 0.46-0.79; p=0.0002), while oxaliplatin-based regimen group had higher neurosensory toxicity (OR=2.21, 95% CI 1.52-3.21; p<0.0001), In addition, gastrointestinal toxicity was similar between the two groups (OR=1.01, 95% CI 0.5-2.01; p=0.27).ConclusionsCompared with cisplatin-based regimen, oxaliplatin-based regimen treatment has an obvious advantage in patients with GC with acceptable tolerance.